Has Francisco Munoz received payments from drug or device companies?

Yes. Drug and device makers reported $303,187 in general payments to Francisco Munoz across 1,143 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Francisco Munoz did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Francisco Munoz come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Francisco Munoz

Internal Medicine · Elizabeth, NJNPI 1164484291

Payments from drug & device makers

$303,187in general payments, 2019–2025

Across 1,143 payments — averaging $265.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$261K
Pfizer$26K
Amgen$4K
GSK$2K
Novo Nordisk$1K
AstraZeneca$1K
plus $8K from 49 others

$946in research payments, 2019–2025

Across 11 payments — averaging $86.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$946

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	208	$261,091
Pfizer	85	$25,937
Amgen(2 entities)	94	$3,604
GSK	72	$1,534
Novo Nordisk	98	$1,291
AstraZeneca	82	$1,259
Boehringer Ingelheim	57	$1,093
Sanofi-aventis U.S. LLC	59	$982
Amarin Pharma, Inc.	39	$604
Lilly USA, LLC	43	$595
Novartis	38	$497
Bayer	19	$472
Johnson & Johnson	32	$434
Merck	31	$433
Exact Sciences	16	$353
Qiagen, LLC	5	$321
Ironwood Pharmaceuticals, Inc	20	$320
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	17	$244
Ardelyx, Inc.	12	$234
Dexcom, Inc.	11	$222
Sanofi	4	$159
Takeda Pharmaceuticals U.S.A., Inc.	12	$153
Corcept Therapeutics	8	$129
Otsuka America Pharmaceutical, Inc.	6	$120
Nestle Healthcare Nutrition Inc.	7	$110
Kowa Pharmaceuticals America, Inc.	7	$96
Lundbeck LLC	4	$70
Astellas Pharma US Inc	5	$70
Daiichi Sankyo Inc.	5	$69
Mannkind Corporation	4	$58
E.r. Squibb & Sons, L.L.C.	4	$55
Arbor Pharmaceuticals, Inc.	4	$50
Phathom Pharmaceuticals, Inc.	3	$46
Scilex Pharmaceuticals Inc.	3	$43
Vifor Pharma, Inc.	3	$43
Abbott	2	$32
Xeris Pharmaceuticals, Inc.	2	$31
Teva Pharmaceuticals USA, Inc.	2	$29
Althera Pharmaceuticals LLC	2	$29
Radius Health, Inc.	2	$28
BD	2	$24
Medtronic	1	$21
Edwards Lifesciences	1	$20
Sunovion Pharmaceuticals Inc.	1	$20
Biogen	1	$18
Cequr Corporation	1	$16
Regeneron Healthcare Solutions, Inc.	1	$15
Sanofi Pasteur Inc.	1	$15
Biohaven Pharmaceutical Holding Company Ltd.	1	$15
Shield Therapeutics Inc	1	$15
Idorsia Pharmaceuticals US Inc	1	$14
Seqirus USA Inc	1	$14
Esperion Therapeutics, Inc.	1	$14
Gilead	1	$14
Optinose US, Inc.	1	$14

How this compares

$303,187 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024

$86,697

Medicare patients

171

Services billed

1,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Elizabeth

Sanjiv SharmaToms River$33.9M
Jeffrey CarsonNew Brunswick$13.8M
Samer HaddadHamilton$6.8M
Magdy ShenoudaWall$3.7M
Samar HameedLivingston$3.6M
Jane RohlfTrenton$2.7M
Mohammed NisarEdison$2.6M
Michael CasserNew Milford$2.2M
Sumitha ReddyHamilton$2M
Helio PedroNewark$1.8M

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →